Global /Japan /Healthcare /Medical Care Facilities /7774

Japan Tissue Engineering Co., Ltd.

7774

• TSE: 7774 • Delayed

530JPY -0.8%

3.31 USD

As of 6 June 2026, Japan Tissue Engineering Co., Ltd. has a market cap of $135.51M USD, ranking #23509 globally and #1990 in Japan. It ranks #2113 in the Healthcare sector, and #248 in the Medical Care Facilities industry.

Global Rank

23509

Country Rank

1990

Sector Rank

2113

Industry Rank

248

Key Stats

Market Cap

$135.51MUSD

21.69B JPY

Enterprise Value

$114.57MUSD

18.35B JPY

Revenue (TTM)

$14.11MUSD

2.26B JPY

Net Income (TTM)

-$2.88MUSD

-461.45M JPY

Profit Margin

-20%

PS Ratio

9.6

PB Ratio

4.1

Company Profile

Country (HQ)

Japan

Sector

Healthcare

Industry

Medical Care Facilities

CEO

Kazuto Yamada open_in_new

Employees

204

Founded

1999

Website

jpte.co.jp open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-0.8%	-13%	-23%	-7.1%	8.3%	-14%	-15%	-7.6%	-21%

News

Markets

Exchange	Ticker	Price	Quotes
Tokyo Stock Exchange (TSE / TYO) MIC: XTKS PRIMARY	7774 株式会社ジャパン・ティッシュエンジニアリング ISIN: JP3389610001 Shares Out.: Shares Outstanding: 40.61M¹ Shares Float: 11.05M² TV: TradingView: TSE: 7774 SA: Stock Analysis: TYO: 7774 YF: Yahoo Finance: 7774.T GF: Google Finance: TYO: 7774 BA: Barron's: 7774 MS: Morningstar: XTKS: 7774	530 JPY	TV: TradingView: TSE: 7774 SA: Stock Analysis: TYO: 7774 YF: Yahoo Finance: 7774.T GF: Google Finance: TYO: 7774 BA: Barron's: 7774 MS: Morningstar: XTKS: 7774

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Japan Tissue Engineering Co., Ltd.

Japan Tissue Engineering Co., Ltd. engages in the regenerative medicine business in Japan. The company operates through Regenerative Medicine Product, Regenerative Medicine Contract, and Research and Development Support segments. It offers autologous cultured epidermis, cartilage, corneal epithelium, and oral mucosal epithelium to medical institutions for the purpose of medical treatment. The company also provides tissue-engineered medical products. In addition, it researches and develops human 3-dimensional cultured tissue models for use in the development of cosmetics and drugs for external use, as well as in research that employs skin and cornea tissues. Further, the company offers regenerative medicine contract development and manufacturing services. The company was founded in 1999 and is headquartered in Gamagori, Japan. Japan Tissue Engineering Co., Ltd. operates as a subsidiary of Teijin Limited.

Similar Companies

Industry: Medical Care Facilities (Japan)

Name	Market Cap (USD) diff.	PE	Country
H.U. Group Holdings, Inc. TSE: 4544	$1.08B 172.62B JPY 696%	31.6	Japan
BML, Inc. TSE: 4694	$895.94M 143.37B JPY 561%	19.5	Japan
Charm Care Corp. TSE: 6062	$263.65M 42.19B JPY 95%	12.8	Japan
Amvis Holdings, Inc. TSE: 7071	$238.92M 38.23B JPY 76%	11.3	Japan
I'rom Group Co., Ltd. TSE: 2372	$211.05M 33.77B JPY 56%	41.8	Japan
Saint-Care Holding Corp. TSE: 2374	$186.75M 29.88B JPY 38%	17.8	Japan

Industry: Medical Care Facilities (Global)

Name	Market Cap (USD) diff.	PE	Country
International Holding Company PJSC ADX: IHC	$232.18B 852.82B AED 171K%	44.1	United Arab Emirates
HCA Healthcare, Inc. NYSE: HCA	$96.73B 71K%	14.9	United States
Fresenius SE & Co. KGaA XETRA: FRE	$26.68B 22.97B EUR 20K%	15.0	Germany
Koninklijke Philips N.V. AMS: PHIA	$25.58B 22.02B EUR 19K%	24.9	Netherlands
Dr. Sulaiman Al Habib Medical Services Group Co. TADAWUL: 4013	$22.48B 84.42B SAR 16K%	35.2	Saudi Arabia
Labcorp Holdings Inc. NYSE: LH	$21.13B 15K%	24.6	United States

chevron_leftBack